Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Actemra in Rheumatoid Arthritis
NCT00144651Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2001
- Primary completion
- Jun 2009
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: ACR 20% Responder Rate and Frequency and Severity of Adverse Events. Started Aug 2001; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00144651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144651.